NCT04742153招募中2 期
A Multicenter, Non-randomized, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 66
- 试验地点
- 2
- 主要终点
- Objective Response Rate (ORR) by Independent Review Committee(IRC)
研究概览
简要总结
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-low locally advanced or metastatic BC.
详细描述
The study will be conducted in two parts. The first part is efficacy exploration and the second part is efficacy verification. During the course of efficacy exploration, 33 subjects will be enrolled to preliminarily evaluate the safety and efficacy of MRG002. The second part will be adjusted according to the result of the first part. 29 subjects are planned to be enrolled. Considering the dropout rate of 10%, approximately 33 subjects are planned to be enrolled. A total of 66 subjects are planned to be enrolled in efficacy exploration and verification.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary to sign the ICF and follow the requirements specified in the protocol;
- •Aged ≥ 18, both genders;
- •Expected survival time ≥ 12 weeks;
- •The score of ECOG for performance status is 0 or 1;
- •Subjects with histologically confirmed HER2-low breast cancer, are currently in the locally advanced or metastatic stage, and are ineligible for radical excision, and have received at least first-line standard treatment for recurrent or metastatic breast cancer;
- •Archival or biopsy tumor specimens should be provided;
- •Subjects must have imaging evidence of tumor progression during or after the most recent treatment confirmed by the investigator and at least one measurable lesion at the baseline according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.1);
- •Prior anti-tumor treatment-related AEs (NCI CTCAE v5.0 Criteria) have recovered to ≤ Grade 1 (except for alopecia, non-clinically significant or asymptomatic laboratory abnormalities);
- •No severe cardiac dysfunction with left ventricular ejection fraction (LVEF) ≥ 50%;
- •The level of organ functions must meet the basic requirements;
- •Reproductive male subjects and female subjects of childbearing age shall be willing to take effective contraceptive measures from the date signing the ICF to 6 months after the last dose of the IP.
排除标准
- •With previous history of other primary malignancies;
- •Received chemotherapy, radiotherapy, biotherapy, immunotherapy, or other anti-tumor drugs within 4 weeks prior to the first dose;
- •The subjects have central nervous system (CNS) metastasis;
- •Subjects with clinical symptoms of pleural effusion, seroperitoneum or pericardial effusion, for which treatment by puncture and drainage is required;
- •Subjects with peripheral neuropathy of greater than Grade 2 (NCI CTCAE v5.0);
- •Any severe or uncontrolled systemic disease;
- •Patients with poorly controlled heart disease;
- •Evidence of active infection, including but not limited to hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection, uncontrolled active bacterial infection, infection caused by other viruses, fungi, rickettsia or parasites;
- •History of hypersensitivity to any component of MRG002 or history of hypersensitivity of ≥ Grade 3 to trastuzumab injection;
- •Disease progression or recurrence occurred during or after the previous treatment, without evidence of CT/MRI examination results;
- •Subjects with uncontrolled concurrent diseases may have limited ability to obey the study requirements or impaired ability to sign the written ICF;
- •Subjects with active autoimmune disease or a history of autoimmune disease are receiving immunosuppressive agents or systemic hormone therapy, and are still receiving within 2 weeks prior to enrollment;
- •Received anti-tumor vaccine treatment 4 weeks prior to the first dose, or plan to participate in anti-tumor vaccine studies;
- •History of interstitial pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc;
- •Pulmonary embolism or deep vein thrombosis occurred within 3 months prior to the first dose;
- •Female subjects with positive result in serum pregnancy test, or female subjects within lactation period and do not agree to take adequate contraceptive measures during the trial and 6 months after receiving the IP;
- •Other conditions inappropriate for participation in this study, as deemed by the investigator.
研究组 & 干预措施
MRG002
Experimental
MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
干预措施: MRG002 (Drug)
结局指标
主要结局
Objective Response Rate (ORR) by Independent Review Committee(IRC)
时间窗: Baseline to study completion (12 months)
ORR was defined as the proportions of subjects with a complete response (CR) and partial response (PR). ORR will be assessed by Independent Review Committee (IRC) according to RECIST v1.1.
次要结局
- Progression Free Survival (PFS)(Baseline to study completion (12 months))
- Pharmacokinetics (PK) parameter for MRG002: concentration-time curve(Baseline to 14 days after decision to discontinue treatment)
- Overall Survival (OS)(Baseline to study completion (12 months))
- Objective Response Rate (ORR) by Investigator(Baseline to study completion (12 months))
- 6-month and 12-month Progression Free Survival Rate (PFSR)(Baseline to study completion (12 months))
- Immunogenicity(Baseline to 14 days after decision to discontinue treatment)
- Time to Response (TTR)(Baseline to study completion (12 months))
- Duration of Response (DoR)(Baseline to study completion (12 months))
- Disease Control Rate (DCR)(Baseline to study completion (12 months))
- Incidence of Adverse Events (AEs)(Baseline to 30 days after the last dose of study treatment)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.Locally Advanced Gastric CancerMetastatic HER2 Positive Gastroesophageal Junction CancerNCT05141747Shanghai Miracogen Inc.60
进行中（未招募）
2 期
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaRecurrent or Metastatic Nasopharyngeal CarcinomaNCT05126719Lepu Biopharma Co., Ltd.238
已完成
2 期
A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract CancerAdvanced or Metastatic Biliary Tract CancerNCT04838964Lepu Biopharma Co., Ltd.15
Unknown
2 期
A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium CancerLocally Advanced Urothelial CancerMetastatic Urothelial CarcinomaNCT04839510Shanghai Miracogen Inc.58
Unknown
2 期
A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract CancerAdvanced or Metastatic Biliary Tract CancerNCT04837508Shanghai Miracogen Inc.86